CLDINYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as CLDWW
Calidi Biotherapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.78−0.05 (-6.40%)
Close on Oct 19, 2026
- Market cap
- $1.11M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$24.4966 (−96.90%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.EarningsSplit
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $1.11M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.35
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$17.47M
- EPS, diluted
- -$5.95
- Book value per share
- $2.21
- Diluted shares
- 1M
Five years at a glance
Fiscal years 2021 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$17.85M
Net income
-$17.47M
EPS, diluted
–
Reported periodTrailing twelve months